Abstract 2139P
Background
Long-term cancer survivors (LS), patients over 5 years free of disease, are a population on the rise due to oncological advances. Our aim is to explore QLACS in long-term cancer survival patients in Spain. As a secondary objective is to study their clinical and sociodemographic characteristics and their preference for social media or face-to-face meetings to obtain oncological information.
Methods
We carried out a transversal study in a sample of LS patients from several Spanish hospitals. They completed QLACS, FERREL, SPF12 and social media data. Different types of tumor were included. Psychometric properties of the QLACS were evaluated. Principal component analysis with Varimax rotation was applied to explore the dimensional structure. Pearson’s correlation (Pc) was used to study associations of QLACS with temporal variables. Student’s t test was used to study differences between them.
Results
N= 257, women=59,9 %, < 65 years=55%. Types Tumor: 33% breast, 27% colorectal, 8,9% urothelial, 7,4% other digestive tumors, 7% orl-lung. Factor analysis showed a 12-component solution accounts for 71.03 % of the variance, showing a similar comparable dimensional structure with QLACS. Alfa Cronbach=0,9. Appearance concern, distress over recurrence, pain, negative feelings and distress familiar are statistically higher in female (p<0,05). We found negative correlation between age and use of social networks for oncological information (Facebook: p = 0.01, Pc: -248; Twitter: p<0.04, Pc:- 200; Instagram: p <0.007, Pc: -259 except; Youtube: p = 0.17; Pc: -134). No differences by sex were observed in the use of social networks There were no differences by age in attending face-to-face meetings: p< 0.94, Pc: - 196. Breast cancer patients are more willing to attend face-to-face meetings to help other patients than those with colon cancer (p< 0.036).
Conclusions
QLACS is a valid and reliable instrument for measuring quality of life in long-term cancer survivors in Spain. Younger patients are more likely to use social media for oncology information. Older people tend to prefer face-to-face meetings. We found differences between men and women in different factors for measuring quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Cornide.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07